These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15362178)

  • 1. Money for health: the equivalent variation of cardiovascular diseases.
    Groot W; Van Den Brink HM; Plug E
    Health Econ; 2004 Sep; 13(9):859-72. PubMed ID: 15362178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The subjective costs of health losses due to chronic diseases. An alternative model for monetary appraisal.
    Ferrer-i-Carbonell A; van Praag BM
    Health Econ; 2002 Dec; 11(8):709-22. PubMed ID: 12457371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The cost per year of life gained: trends and internal contradictions].
    Smulders YM; Thijs A
    Ned Tijdschr Geneeskd; 2006 Nov; 150(45):2467-70. PubMed ID: 17137090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care costs in the last year of life--the Dutch experience.
    Polder JJ; Barendregt JJ; van Oers H
    Soc Sci Med; 2006 Oct; 63(7):1720-31. PubMed ID: 16781037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The compensating income variation of cardiovascular disease.
    Groot W; van den Brink HM
    Health Econ; 2006 Oct; 15(10):1143-8. PubMed ID: 16615037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive health screenings and health consultations in primary care increase life expectancy without increasing costs.
    Rasmussen SR; Thomsen JL; Kilsmark J; Hvenegaard A; Engberg M; Lauritzen T; Søgaard J
    Scand J Public Health; 2007; 35(4):365-72. PubMed ID: 17786799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deriving welfare measures from discrete choice experiments: inconsistency between current methods and random utility and welfare theory.
    Lancsar E; Savage E
    Health Econ; 2004 Sep; 13(9):901-7. PubMed ID: 15362181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of acupuncture in women and men with allergic rhinitis: a randomized controlled study in usual care.
    Witt CM; Reinhold T; Jena S; Brinkhaus B; Willich SN
    Am J Epidemiol; 2009 Mar; 169(5):562-71. PubMed ID: 19126587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.